Multi-Epitope mRNA HIV Vaccine for Mutation-Resistant Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional HIV vaccines have limited success due to high mutation rates and variable strains, and the challenge lies in inducing a robust immune response against both surface and conserved internal proteins like capsid, which are less accessible and pose risks of off-target effects.
Innovation Solution
A therapeutic HIV mRNA combination vaccine formulated with lipid nanoparticles, encoding conserved and immunogenic epitopes of HIV gp160 proteins and capsid p24, along with Nef protein epitopes, to stimulate both humoral and cellular immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional vaccination strategies are used, then the vaccine can be administered using traditional methods, but the immune response is limited due to high mutation rates and variable strains of HIV
Solution Approach 1:
The vaccine composition targets multiple conserved epitopes across different HIV strains (HIV-1 and HIV-2), including gp160, capsid p24, and Nef protein epitopes. This multi-epitope approach enables the vaccine to provide broad protection against various HIV strains simultaneously, resolving the contradiction between reliability for specific strains and adaptability to multiple strains.
Solution Approach 2:
The patent uses modified nucleoside mRNA technology to encode multiple conserved epitopes, changing the fundamental parameter of vaccine composition from single-antigen traditional vaccines to multi-epitope mRNA vaccines. This parameter change enables the vaccine to maintain reliability while achieving versatility across different HIV strains through targeted conserved regions.
2Reliability
If the vaccine targets conserved internal proteins like capsid, then it can overcome viral mutation challenges, but these proteins are less accessible and pose risks of off-target effects
Solution Approach 1:
The vaccine merges multiple epitope targets including surface proteins (gp160), internal proteins (capsid p24), and regulatory proteins (Nef) into a single composition. This combination strategy allows the vaccine to target conserved internal proteins for mutation resistance while also including surface proteins that are more accessible, thereby reducing off-target effects through balanced multi-target approach.
Solution Approach 2:
The modified nucleoside mRNA acts as an intermediary that delivers multiple epitope sequences to host cells, enabling the expression of conserved internal proteins in a controlled manner. This intermediary approach allows safe presentation of internal protein epitopes that would otherwise be inaccessible, reducing off-target effects through regulated antigen expression.
3Adaptability or versatility
If the vaccine uses multiple mRNA molecules or combined single molecule, then it can express multiple epitopes, but the formulation and delivery complexity increases
Solution Approach 1:
The patent merges multiple epitope-encoding sequences into either multiple separate mRNA molecules or a single combined mRNA molecule expressing all epitopes. This merging strategy simplifies the formulation compared to using multiple separate vaccines, while still achieving versatile multi-epitope expression through the unified mRNA delivery system.
Solution Approach 2:
The lipid nanoparticle delivery system serves as a universal platform that can deliver multiple mRNA molecules or a single multi-epitope mRNA molecule. This multi-functional delivery system handles the complexity of multiple epitopes internally, presenting a simplified single-dose vaccine formulation to the patient.
Data Source
AI summary
The Human Immunodeficiency Virus (HIV) infection and recurrent infection prevention mRNA vaccine comprising epitopes of HIV-1 and HIV-2 viruses and their corresponding Nef proteins.